SHANGHAI, April 9, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the first cohort of healthy volunteers has been dosed in a phase I clinical trial of AK0406, a novel long-acting antiviral drug-Fc conjugate (ADFC) drug for influenza infection, following approval by the Human Research Ethics Committee (HREC) in Australia. This milestone marks the first-in-human (FIH) evaluation of AK0406 and an important step in the global clinical development of Ark

Digital health and clinical platforms can now operationalize Galleri seamlessly through Junction's ordering and diagnostic infrastructure. SAN FRANCISCO, Apr. 9, 2026 /PRNewswire/ -- Junction, the infrastructure platform for diagnostic testing and health data workflows, today announced a collaboration with GRAIL to support scalable access to the Galleri® multi-cancer early detection test across digital health platforms and clinical organizations. Through Junction's diagnostic infrastructure, hea

Professor Belvisi joins from AstraZeneca, where she served as Senior Vice President, Research & Development, Respiratory & Immunology and built one of the most productive early R&D organizations in global pharma, including leading tozorakimab from preclinical research through Phase 3 investment decision — a program that recently delivered landmark wins in two pivotal COPD trials Her appointment accelerates Ailux's evolution from AI-native biologics discovery into a fully integrated drug developm

SHANGHAI, April 9, 2026 /PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell"), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies, today announced the cumulative closing of a pre-IPO financing round in excess of $110 million. The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund. The syndicate included an international sovereign wealth fund,

Melbourne (Australia) and Indianapolis (United States) | April 10, 2026 Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Company’s resubmitted New Drug Application (NDA) for TLX101-Px[1], (Pixclara®[2], Floretyrosine F 18 or 18F-FET), an investigational PET[3] agent for the imaging of glioma (brain cancer), and has assigned a PDUFA[4] goal date of September 11, 2026. The approval of TLX101-Px will fulfil a significant unmet medical need for

SAN FRANCISCO and SUZHOU, China, April 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, presented for the first time the preclinical data of IBI3055, a proprietary anti-CD19/BCMA/CD3 tri-specific T cell engager for the treatment of autoimmune

SOUTH SAN FRANCISCO, Calif., April 9, 2026 /PRNewswire/ -- Human Longevity, Inc. (HLI), a global leader in precision health and longevity medicine, today announced that artificial intelligence pioneer and Nobel Prize–winning scientist Geoffrey Hinton has joined the company as a Scientific Advisor. In this role, Dr. Hinton will help guide HLI's AI strategy as it builds a next-generation platform for disease-risk prediction and early detection. Dr. Hinton, widely regarded as one of the "godfathers

Aiva Nurse Assistant brings voice-enabled clinical support to Zebra ' s HC20/HC50 mobile computers and new WS101-H badge devices LINCOLNSHIRE, Ill. and LOS ANGELES, April 9, 2026 /PRNewswire/ -- Zebra Technologies Corporation (NASDAQ: ZBRA), a global leader in digitizing and automating workflows to deliver intelligent operations, and Aiva Health, a pioneer in voice-powered clinical software, today announced a partnership to support hands-free nurse workflows using Aiva's AI-powered Aiva Nurse

Multi-phase program targets deployment of an integrated intelligence platform enabling up to 200 humanoid robots to operate within real clinical workflows SANTA CLARA, Calif., April 9, 2026 /PRNewswire/ -- Lightwheel, a Physical AI infrastructure company, and PeritasAI, a perioperative intelligence and orchestration company, today announced a strategic partnership to combine PeritasAI's agentic orchestration platform with Lightwheel's Physical AI infrastructure to enable robots to train, validat

In a crowded field, a new mechanism appears: environmental change & microbiome support ARLINGTON HEIGHTS, Ill., April 9, 2026 /PRNewswire/ -- NeuEve, a leading research lab & manufacturer of natural remedies for women's health, announces the launch of Yeast Clear. Yeast Clear uses a new approach designed for women experiencing chronic yeast infections. "The high recurrence rate from all other treatments is an opportunity for us to make a positive impact on society," said Dr. Renjie Chang, OBGYN.